Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery

被引:131
|
作者
Özal, E
Kuralay, E
Yildirim, V
Kilic, S
Bolcal, C
Kücükarslan, N
Günay, C
Demirkilic, U
Tatar, H
机构
[1] Gulhane Mil Med Acad, Dept Cardiovasc Surg, Ankara, Turkey
[2] Gulhane Mil Med Acad, Dept Anesthesiol, Ankara, Turkey
[3] Gulhane Mil Med Acad, Dept Publ Hlth & Epidemiol, Ankara, Turkey
来源
ANNALS OF THORACIC SURGERY | 2005年 / 79卷 / 05期
关键词
D O I
10.1016/j.athoracsur.2004.10.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and preoperative intravenous heparin use are independent risk factors for vasoplegic syndrome after cardiac surgery. We prospectively studied whether preoperative methylene blue administration would prevent the vasoplegic syndrome in these high-risk patients. Methods. One hundred patients scheduled for coronary artery bypass graft surgery who were at high risk for vasoplegia because they were preoperatively using angiotensin-converting enzyme inhibitors, calcium channel blockers, and heparin were randomly assigned to either receive preoperative methylene blue (group 1, n = 50) or not receive it (group 2, controls, n = 50). Methylene blue (1% solution) was administered intravenously at a dose of 2 mg/kg for more than 30 minutes, beginning in the intensive care unit 1 hour before surgery. Results. Although similar in terms of all demographic and operative variables, the two groups differed significantly in terms of vasoplegic syndrome incidence (0% in group 1[0 of 50] vs 26% in group 2 [13 of 50]; p < 0.001). In 6 patients, the vasoplegic syndrome was refractory to norepinephrine. Four of these patients survived; the other 2 had vasoplegic syndromes that were refractory to aggressive vasopressor therapy, and they ultimately died of multiorgan failure. Stroke occurred in 1 patient. The two study groups also differed significantly in terms of average intensive care unit stay (1.2 +/- 0.5 days in group 1 vs 2.1 +/- 1.2 days in group 2; p < 0.001) and average hospital stay (6.1 +/- 1.7 days in group 1 vs 8.4 +/- 2.0 days in group 2; p < 0.001). Conclusions. Our results suggest that preoperative methylene blue administration reduces the incidence and severity of vasoplegic syndrome in high-risk patients, thus ensuring adequate systemic vascular resistance in both operative and postoperative periods and shortening both intensive care unit and hospital stays. (c) 2005 by The Society of Thoracic Surgeons.
引用
收藏
页码:1615 / 1619
页数:5
相关论文
共 50 条
  • [1] Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery
    Lenglet, Sebastien
    Mach, Francois
    Montecucco, Fabrizio
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (12) : 1519 - 1525
  • [2] Methylene Blue for Vasoplegic Syndrome Postcardiac Surgery
    Habib, Aly Makram
    Elsherbeny, Ahmed Galal
    Almehizia, Rayd Abdelaziz
    [J]. INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2018, 22 (03) : 168 - 173
  • [3] Serotonin Syndrome Following Methylene Blue Administration for Vasoplegic Syndrome
    Hencken, Laura
    To, Long
    Ly, Nancy
    Morgan, Jeffrey A.
    [J]. JOURNAL OF CARDIAC SURGERY, 2016, 31 (04) : 208 - 210
  • [4] Methylene Blue for Vasoplegic Syndrome After Cardiac Operations
    Cakir, Habib
    Yurekli, Ismail
    Celik, Ersin
    Gungor, Hilmi
    Kestelli, Mert
    [J]. ANNALS OF THORACIC SURGERY, 2019, 107 (02): : 685 - 686
  • [5] Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival
    Mehaffey, J. Hunter
    Johnston, Lily E.
    Hawkins, Robert B.
    Charles, Eric J.
    Yarboro, Leora
    Kern, John A.
    Ailawadi, Gorav
    Kron, Irving L.
    Ghanta, Ravi K.
    [J]. ANNALS OF THORACIC SURGERY, 2017, 104 (01): : 36 - 41
  • [6] Methylene Blue for Vasoplegic Syndrome
    Booth, Alexander T.
    Melmer, Patrick D.
    Tribble, J. Benjamin
    Mehaffey, J. Hunter
    Tribble, Curt
    [J]. HEART SURGERY FORUM, 2017, 20 (05): : E234 - E238
  • [7] Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery
    Levin, RL
    Degrange, MA
    Bruno, GF
    Del Mazo, CD
    Taborda, DJ
    Griotti, JJ
    Boullon, FJ
    [J]. ANNALS OF THORACIC SURGERY, 2004, 77 (02): : 496 - 499
  • [8] METHYLENE BLUE ADMINISTRATION IN REFRACTORY VASOPLEGIC TOXIC SHOCK SYNDROME
    Taylor, Jonathan
    Nonas, Stephanie
    [J]. CHEST, 2020, 158 (04) : 902A - 902A
  • [9] Methylene Blue for Vasoplegic Syndrome After Cardiac Operations Reply
    Mehaffey, J. Hunter
    [J]. ANNALS OF THORACIC SURGERY, 2019, 107 (02): : 686 - 686
  • [10] The additional use of methylene blue has a decatecholaminisation effect on cardiac vasoplegic syndrome after cardiac surgery
    Petermichl, Walter
    Gruber, Michael
    Schoeller, Ina
    Allouch, Kwahle
    Graf, Bernhard M.
    Zausig, York A.
    [J]. JOURNAL OF CARDIOTHORACIC SURGERY, 2021, 16 (01)